Novakand Pharma is developing a new class of orphan drugs focused on overcoming treatment resistance in advanced ovarian cancer and blood cancer.
Novakand Pharma operates out of the Karolinska Institutet Science Park in Solna, a world-leading center for medical innovation. The company is developing a new class of small-molecule drug candidates that precisely target cancer cells and disease-promoting immune cells by blocking the fractalkine axis.
Novakand Pharma is developing two “best-in-class” low-molecular-weight drug candidates that can be administered orally, both of which are in the clinical development phase
Novakand Pharma’s drug development strategy is based on synthetic small molecules that are best-in-class and have the potential to slow the progression of cancer in a well-defined patient group with advanced rare diseases. This patient group is defined using biomarkers in blood or tumors, which provides a strong foundation for achieving treatment success in a significant proportion of this vulnerable patient population and for obtaining orphan drug designation. For these orphan drugs—developed specifically to diagnose, prevent, or treat rare diseases—regulatory authorities provide financial incentives such as attractive pricing and extended market exclusivity, provided that performance requirements are met upon market launch.
Another key component of the business model is partnerships with researchers, healthcare providers, patient organizations, and industry, with the aim of designing Novakand’s products to best meet medical needs and market performance requirements. Commercialization through industrial partnerships involves Novakand licensing out rights for the development and commercialization of its drug candidates. This is initially done in exchange for milestone payments during clinical development and subsequently through royalties on future sales. This may take place on a global basis or within specific geographic regions.
Under this business model, Novakand Pharma can generate revenue in the form of sales in markets where the company chooses to retain development and commercialization rights. In markets where rights are out-licensed, the company instead receives payments from partners which typically include upfront and milestone payments, as well as royalty income from sales.
Collaborations and partnerships are central components of Novakand Pharma’s business model.
The company’s strategy is to develop and commercialize its drug candidates through partnerships with internationally established pharmaceutical companies that focus on orphan drugs and cancer.
Please contact our CEO, Thomas Olin, regarding partnerships: thomas.olin@novakand.com.
Novakand Pharma’s management team has extensive expertise and international experience of translating medical discovery into candidate drugs and developing these into marketed products.
Management
Management
Novakand Pharma's board of directors consists of individuals with extensive experience from senior positions in their respective areas of expertise.
Board
Board
Board
Board
Please contact CEO Thomas Olin for any collaboration, business development or licensing enquiries:
Investor relations and enquires from shareholders, news agencies and media are managed by Novakand Pharma’s Communications team. For any IR enquires please contact:
General enquires are managed by Novakand Pharma’s Communications team, please contact: